HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Heart Test Laboratories, Inc. (NASDAQ: HSCS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $15.00 price target on the stock.
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission